Harrow secures TYRVAYA rights and adds a 2027 test for Harrow Health stock

Published on 10/16/2026 at 01:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Harrow paid USD 30.00 million and may owe USD 70.00 million in milestones. TYRVAYA could add USD 30.00 million of 2027 revenue to Harrow Health stock.

TYRVAYA expands Harrow's platform

Harrow closed the TYRVAYA acquisition on October 5, 2026, with USD 30.00 million paid at closing.
Second-quarter 2026 revenue reached USD 70.66 million, while GAAP net loss was USD 17.27 million.
Harrow stock was last at USD 28.75 on October 15, 2026, with a USD 1.1 billion market capitalization.

HROW, US4158581094, Illustration mit AI erstellt.

Harrow Health (ISIN US4158581094) closed its acquisition of TYRVAYA on October 5, 2026, paying USD 30.00 million in cash and agreeing to as much as USD 70.00 million in contingent milestones, according to Globe Newswire. The deal gives Harrow worldwide TYRVAYA rights except Japan and adds a second differentiated dry-eye treatment beside VEVYE.

Three milestones shaped the expansion

On August 11, 2026, Harrow listed its second-quarter earnings call, with revenue for the quarter ended June 30 reaching USD 70.66 million. On September 30, 2026, Harrow said 15 scientific presentations would feature its ophthalmic portfolio at two industry meetings, according to Globe Newswire. On October 5, 2026, the company closed the TYRVAYA transaction for the USD 30.00 million upfront payment.

What does TYRVAYA add?

The commercial opportunity is measurable. Harrow expects TYRVAYA to contribute more than USD 30.00 million in revenue during 2027, while approximately 40 Viatris personnel are expected to join during the fourth quarter of 2026, according to Globe Newswire. The integration is designed to use one commercial organization for TYRVAYA and VEVYE, which could broaden prescriber reach while keeping the two products' different administration routes.

The next operating milestone

Commercial integration is scheduled to begin in the fourth quarter of 2026, when the incoming team is expected to support both dry-eye brands. That timing makes 2027 revenue execution the clearest operating test following the acquisition.

Market value frames the deal

Harrow reported USD 70.66 million in second-quarter 2026 revenue and a GAAP net loss of USD 17.27 million, compared with USD 63.74 million of revenue and a USD 5.00 million net profit in the prior-year quarter, according to Markets Insider. Harrow's latest quoted market capitalization was USD 1.1 billion on October 15, 2026, and its 52-week range was USD 26.96 to USD 54.85.

Stock remains tied to execution

Harrow was last at USD 28.75 on October 15, 2026 at 4:00 p.m. ET on Nasdaq. The quote sat above the 52-week low but below the 52-week high, leaving the TYRVAYA rollout and the 2027 revenue contribution as the next concrete measures of the strategy.